Gunnar Cario
Overview
Explore the profile of Gunnar Cario including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
3294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tang M, Antic Z, Fardzadeh P, Pietzsch S, Schroder C, Eberhardt A, et al.
EBioMedicine
. 2024 May;
104:105171.
PMID: 38810562
Background: The increasing volume and intricacy of sequencing data, along with other clinical and diagnostic data, like drug responses and measurable residual disease, creates challenges for efficient clinical comprehension and...
12.
Gentile G, Poggio T, Catalano A, Voutilainen M, Lahnalampi M, Andrade-Martinez M, et al.
Blood Adv
. 2024 Apr;
8(11):2846-2860.
PMID: 38598725
The t(1;19) translocation, encoding the oncogenic fusion protein E2A (TCF3)-PBX1, is involved in acute lymphoblastic leukemia (ALL) and associated with a pre-B-cell receptor (preBCR+) phenotype. Relapse in patients with E2A-PBX1+...
13.
Kroeze E, Iaccarino I, Kleisman M, Mondal M, Beder T, Khouja M, et al.
Blood
. 2024 Apr;
144(1):74-83.
PMID: 38588489
Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in the bone marrow or blood (BCP acute lymphoblastic leukemia [BCP-ALL]) or are less common in extramedullary tissue (BCP...
14.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, et al.
Blood
. 2024 Mar;
143(26):2735-2748.
PMID: 38518105
Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of B-cell precursors (BCP-ALL) or T cells (T-ALL). Current treatment protocols obtain high cure rates in children but are based on...
15.
Junk S, Forster A, Schmidt G, Zimmermann M, Fedders B, Haermeyer B, et al.
Leukemia
. 2024 Feb;
38(4):887-892.
PMID: 38413718
No abstract available.
16.
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, et al.
Haematologica
. 2024 Feb;
109(12):3892-3903.
PMID: 38356450
The ongoing development of immunotherapies, including chimeric antigen receptor (CAR) T cells, has revolutionized cancer treatment. In pediatric relapsed/refractory B-lineage acute leukemia antiCD19-CAR induce impressive initial response rates, with event-free...
17.
Moser O, Ngoya M, Galimard J, Dalissier A, Dalle J, Kalwak K, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):604-614.
PMID: 38331982
Peripheral T-cell lymphomas (PTCL) other than anaplastic large-cell lymphoma are rare in children, and the role of hematopoietic stem cell transplantation (HSCT) has not been clarified yet. In a retrospective...
18.
Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Bruggemann M, et al.
Blood
. 2024 Jan;
143(17):1738-1751.
PMID: 38215390
In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 for a...
19.
Bastian L, Beder T, Barz M, Bendig S, Bartsch L, Walter W, et al.
Blood
. 2023 Dec;
143(14):1391-1398.
PMID: 38153913
Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and acute leukemias (ICC): "lymphoid only", with BCR::ABL1 observed exclusively...
20.
Conter V, Valsecchi M, Cario G, Zimmermann M, Attarbaschi A, Stary J, et al.
J Clin Oncol
. 2023 Dec;
42(8):915-926.
PMID: 38096462
Purpose: The AIEOP-BFM ALL 2009 protocol included, at the end of the induction phase, a randomized study of patients with high-risk (HR) ALL to investigate if an intensive exposure to...